Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2003-02-28
2009-12-01
Zucker, Paul A (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S513000, C514S532000, C514S533000, C560S021000, C560S022000, C560S045000, C560S047000, C560S055000
Reexamination Certificate
active
07625948
ABSTRACT:
A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1″)(whereinR1and R2are each hydrogen atom or optionally substituted aryl, etc.;X is —COO— or —CON(R10)—;R3and R4are each hydrogen atom, C1-C6alkyl or C1-C6alkoxy, etc.;R5, R6and R7are each hydrogen atom, C1-C6alkyl or C1-C6alkoxy, etc.;R8and R9are each independently hydrogen atom, C1-C6alkyl, —CON(R18)(R19) or —COO(R20), etc.;ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.;Alk1and Alk2are each independently alkanediyl, etc.;l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either.The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.
REFERENCES:
patent: 5521170 (1996-05-01), Setoi et al.
patent: 5683682 (1997-11-01), Betts
patent: 5684014 (1997-11-01), Muller et al.
patent: 5827875 (1998-10-01), Dickson, Jr. et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 6057339 (2000-05-01), Gregg
patent: 6121283 (2000-09-01), Chang et al.
patent: 6171599 (2001-01-01), Miyamoto et al.
patent: 6211242 (2001-04-01), Setoi et al.
patent: 6235730 (2001-05-01), Sato et al.
patent: 6288234 (2001-09-01), Griffin
patent: 6369075 (2002-04-01), Ruggeri et al.
patent: 6509038 (2003-01-01), Baert et al.
patent: 6617325 (2003-09-01), Lehmann-Lintz et al.
patent: 6713489 (2004-03-01), Ruggeri et al.
patent: 6818644 (2004-11-01), Lehmann-Lintz et al.
patent: 6943185 (2005-09-01), Susilo et al.
patent: 7081255 (2006-07-01), Baert et al.
patent: 2001/0007678 (2001-07-01), Baert
patent: 2002/0012706 (2002-01-01), Vladyka, Jr.
patent: 2002/0028943 (2002-03-01), Griffin
patent: 2002/0032238 (2002-03-01), Priepke et al.
patent: 2003/0044528 (2003-03-01), Tanno et al.
patent: 2003/0114442 (2003-06-01), Heckel et al.
patent: 2004/0058903 (2004-03-01), Takasugi et al.
patent: 2005/0075367 (2005-04-01), Hagiwara et al.
patent: 2006/0030623 (2006-02-01), Furukawa et al.
patent: 2006/0089392 (2006-04-01), Hagiwara et al.
patent: 2006/0153913 (2006-07-01), Yamane et al.
patent: 2006/0205726 (2006-09-01), Hagiwara et al.
patent: 2079938 (1993-04-01), None
patent: 2 291 471 (1999-12-01), None
patent: 2 324 800 (2000-10-01), None
patent: 2 376 881 (2001-01-01), None
patent: 1 099 701 (2001-05-01), None
patent: 1 350 792 (2003-10-01), None
patent: 1 769 793 (2007-04-01), None
patent: 47-25189 (1972-10-01), None
patent: 57-206612 (1982-02-01), None
patent: 3-1288 (1991-01-01), None
patent: 3-28404 (1991-01-01), None
patent: 05-097672 (1993-04-01), None
patent: 07-002800 (1995-01-01), None
patent: 08-179504 (1996-07-01), None
patent: 08-208476 (1996-08-01), None
patent: 9-59159 (1997-03-01), None
patent: 9-309834 (1997-12-01), None
patent: 11-035555 (1999-02-01), None
patent: 11-228569 (1999-08-01), None
patent: 11-509238 (1999-08-01), None
patent: 11-246404 (1999-09-01), None
patent: 2000-169395 (2000-06-01), None
patent: 2000-281561 (2000-10-01), None
patent: 2001-172180 (2001-06-01), None
patent: 2002-220345 (2002-08-01), None
patent: 2003-505373 (2003-02-01), None
patent: 2003-73261 (2003-03-01), None
patent: 2003-509505 (2003-03-01), None
patent: 2003-531099 (2003-10-01), None
patent: 2003-321424 (2003-11-01), None
patent: 2004-10575 (2004-01-01), None
patent: 2004-510763 (2004-04-01), None
patent: 1999-0075252 (1999-10-01), None
patent: WO 9640640 (1996-12-01), None
patent: WO 97/262240 (1997-07-01), None
patent: WO 97/43257 (1997-11-01), None
patent: WP 98/23593 (1998-06-01), None
patent: WO 1998/47875 (1998-10-01), None
patent: WO 99/63929 (1999-12-01), None
patent: WO 00/05201 (2000-02-01), None
patent: WO 2000/32582 (2000-06-01), None
patent: WO 2000/37422 (2000-06-01), None
patent: WO 2000/56726 (2000-09-01), None
patent: WO 01/00183 (2001-01-01), None
patent: WO 01/00184 (2001-01-01), None
patent: WO 01/00189 (2001-01-01), None
patent: WO 2001/05762 (2001-01-01), None
patent: WO 01/12601 (2001-02-01), None
patent: WO 2001/21604 (2001-03-01), None
patent: WO 2001/47898 (2001-07-01), None
patent: WO 2001/47899 (2001-07-01), None
patent: WO 2001/53260 (2001-07-01), None
patent: WO 01/77077 (2001-10-01), None
patent: WO 2001/97810 (2001-12-01), None
patent: WO 02/04403 (2002-01-01), None
patent: WO 2002/20501 (2002-03-01), None
patent: WO 02/28835 (2002-04-01), None
patent: WO 2002/42271 (2002-05-01), None
patent: WO 2002/42291 (2002-05-01), None
patent: WO 02/48141 (2002-06-01), None
patent: WO 2002/051385 (2002-07-01), None
patent: WO 2002/081460 (2002-10-01), None
patent: WO 2002/098839 (2002-12-01), None
patent: WO 2003/072532 (2003-09-01), None
patent: WO 2005/021486 (2005-03-01), None
patent: WO 2006/008962 (2006-01-01), None
patent: WO 2006/043510 (2006-04-01), None
patent: WO 2006/046623 (2006-05-01), None
Fischer et al, Journal of the Chemical Society (B), Rates of Base-catalyzed Hydrolysis of Substituted Aryl Benzoates, 1971, pp. 1818-1819.
Ksander, G. M. et al., “Diaminoindanes as Microsomal Triglyceride Transfer Protein Inhibitors”, Journal of Medicinal Chemistry, 2001, vol. 44, No. 26, pp. 4677-4687 (2001).
Wetterau, J. R. et al., “Purification and Characterization of Microsomal Triglyceride and Cholesteryl Ester Transfer Protein from Bovine Liver Microsomes”, Chemistry and Physics of Lipids, vol. 38, pp. 205-222 (1985).
Robl, Jeffrey A. et al., “A Novel Series of Highly Potent Benzimidazole-Based Microsomal Triglyceride Transfer Protein Inhibitors,” Journal of Medicinal Chemistry , vol. 44, No. 6, (2001) pp. 851-856.
International Search Report of PCT/JP03/02398 dated Jun. 3, 2003.
Aggarwal et al., BMC Cardiovascular Disorders, 2005, 5:30, pp. 1-8.
Anastasiou, Theordore J., et al., “Syntheses of aminosalicylate-based poluanhydride prodrugs: esters, amides, and azos,”Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) 42(2), 121-122 (2001).
Chiou, W.L. et al., Pharmaceutical Application of Solid Dispersion Systems, J. Pharm. Sci. 60 (1971) 1281-1302.
Hagiwara et al., CAPLUS AN 2003:696857 (Feb. 28, 2003), 2 pages only.
Shiomi et al., MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion, European Journal of Pharmacology, vol. 431, pp. 127-131 (2001).
European Search Report of Application No. 04772363.0 dated Jan. 23, 2008.
PCT International Search Report (PCT/JP2004/012407) dated Feb. 15, 2005.
PCT International Search Report (PCT/JP2005/012448) dated Aug. 9, 2005.
PCT International Search Report (PCT/JP2005/019744) dated Dec. 13, 2005.
PCT International Search Report (PCT/JP2005/019041) dated Jan. 24, 2006.
http://www.mayoclinic.com/health/arteriosclerosis-atherosclerosis/DS00525/DSECTION=8.
http://www.mayoclinic.com/health/obesity/DS00314/DSECTION=7.
Rx for Success, Lipid Levels - The Rick of Arteriosclerosis, Prudential Financial, 2002, 2 pages.
http://www.nhlbi.nih.gov/health/dci/Diseases/Cad/CAD—Whatls.html.
Japan Tobacco Inc. Clinical Development (Apr. 27, 2007).
http://cholesterol.about.com/od/treatments/a/mttpinhibitor.htm.
SciFinder Scholar, version 2007.1; Chemical Abstracts Service, Columbus, OH; RN 339202-67-4 (accessed Feb. 6, 2008).
SciFinder Scholar, version 2007.1; Chemical Abstracts Service, Columbus, OH; RN 339202-91-4 (accessed Feb. 6, 2008).
SciFinder Scholar, version 2007.1; Chemical Abstracts Service, Columbus, OH; RN 516466-52-7 (accessed Feb. 6, 2008).
SciFinder Scholar, version 2007.1; Chemical Abstracts Service, Columbus, OH; RN 901355-00-8 (accessed Feb. 6, 2008).
SciFinder Scholar, version 2007.1; Chemical Abstracts Service, Columbus, OH; RN 888922-25-6 (accessed Feb. 6, 2008).
SciFinder Scholar, version 2007.1; Chemical Abstracts Service, Columbus, OH; RN 900909-90-2 (accessed Feb. 6, 2008.
Williams, Spencer J. et al., “Novel Microsomal Triglyceride Transfer Protein Inhibitors,” Expert Opinion on Therapeutic Patents, 2003, 13, 479-88.
Office Action in Copending U.S. Appl. No. 11/250,636 dated Jan. 7, 200
Hagiwara Atsushi
Ikenogami Taku
Kawai Takashi
Madono Kenya
Odani Naoya
Finnegan Henderson Farabow Garrett & Dunner LLP
Japan Tobacco Inc.
Zucker Paul A
LandOfFree
Ester compound and medicinal use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ester compound and medicinal use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ester compound and medicinal use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4143887